Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer Therapies

 Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer Therapies

Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer Therapies

Shots:

  • The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented, de-identified clinical and genomic data to support Merck’s oncology efforts
  • The data will be accessed through M2GEN’s ORIEN which is a network of 18 cancer centers across the US
  • The collaboration provides utility in Merck’s oncology development programs including indications for Keytruda (pembrolizumab)

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: M2gen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post